Immunoglobulins during different treatment regimes in Schnitzler's syndrome.
Rene
R
Thonhofer
D000068879:Adalimumab; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000627:therapeutic use; D007075:Immunoglobulin M / Q000097:blood*; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D010147:Pain Measurement; D011241:Prednisone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D019873:Schnitzler Syndrome / Q000097:blood* / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015415:Biomarkers; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor; D016572:Cyclosporine; D002097:C-Reactive Protein; D000068879:Adalimumab; D001379:Azathioprine; D000068800:Etanercept; D011241:Prednisone; D008727:Methotrexate